What Larissia Treats: Main Uses and Benefits

Larissia is generally utilized to provide women of reproductive age with a reliable method of pregnancy prevention (birth control). This continuous, long-term use is the core therapeutic goal and assists with fertility management and family planning.

The medication is commonly used across multiple therapeutic domains, including managing menstrual cycle symptoms and associated discomforts. Its indications are considered relevant for addressing conditions presenting with severe menstrual pain (dysmenorrhea), excessive blood loss (menorrhagia), and is used in managing conditions that involve achieving a scheduled, predictable menstrual rhythm. Furthermore, it is considered relevant for managing certain androgen-related manifestations, and may assist with easing the symptomatic burden in conditions like hormonal acne.

“This class of medication is relevant for patients seeking both fertility control and support in managing monthly symptomatic discomforts.”

Larissia contributes to easing the overall symptom load associated with recurrent manifestations, supporting patients during episodes of heightened discomfort.

Quick Fact: Relief for Menstrual Symptoms The medication is commonly applied to manage symptom clusters that create noticeable functional strain, such as severe, recurring pain and excessive bleeding, contributing to improved day-to-day comfort.

Regulatory References

1. DailyMed entry supported by the NIH

Eligibility Map: Who Can and Cannot Use Larissia — Official Regulatory Information

Eligibility Scope

Category	Official Regulatory Statements
Populations for whom use is allowed (as stated in label)	Females of reproductive potential; use is indicated only after menarche.
Populations for whom use is not recommended (if applicable)	Nursing mothers, as the medication may decrease milk production.
Populations for whom use is contraindicated	Females over age 35 who smoke. Individuals with current or history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Cerebrovascular Disease, or Coronary Artery Disease. Patients with breast cancer, liver tumors, severe cirrhosis, or uncontrolled hypertension.
Age-related eligibility rules	Use is not indicated in females before menarche or in postmenopausal women.
Condition-specific eligibility rules	Contraindicated in individuals with diabetes mellitus with vascular damage or migraines with focal neurological symptoms or aura.
Pregnancy and lactation eligibility status (if explicitly documented)	The medicine is contraindicated during pregnancy and not recommended during lactation.
Eligibility-related restrictions	Must be discontinued at least four weeks prior to and for two weeks following major surgery or prolonged immobilization.

---

Eligibility Classifications (High-Level)

Category	Classification Details (As Defined in Official Documents)
Eligibility severity classification (as defined in official documents)	Contraindicated (Absolute non-eligibility), Not Recommended, and Not Indicated (Not for use in this population).
Regulatory basis (EMA / FDA / etc.)	Based on the management of risk factors for Venous and Arterial Thromboembolism and Hormone-Sensitive Malignancies.
Eligibility-context constraints (as defined in official documents)	Constraints are primarily tied to Comorbidities, Organ Function (Hepatic), Lifestyle (Smoking), and Postpartum status.

---

Resulting Eligibility Structure

Official eligibility statements:

• The medicine is strictly contraindicated in females over age 35 who smoke, due to a high risk of serious cardiovascular events.
• Use is prohibited in patients with a history of thromboembolic disorders, certain cardiovascular diseases, and hormone-sensitive cancers.
• Use is not indicated in postmenopausal females, establishing that eligibility is strictly limited to females of reproductive potential.

Connection to the overall eligibility profile: Official regulatory documents define who can and cannot use Larissia by establishing clear, non-negotiable contraindications related to cardiovascular risk, specific pre-existing malignancies, and severe hepatic impairment. Eligibility is therefore strictly limited to females of reproductive age who do not present with these specific, officially labeled risk factors or clinical states. The documentation explicitly details these exclusions and conditional restrictions (e.g., before surgery, postpartum) as criteria for patient safety and appropriate use.

Larissia Interactions with other medicines and products

Larissia's official regulatory profile defines interactions through prohibitions, alterations in drug exposure, and specific administration constraints involving co-administered substances.

Formal Prohibited Combinations

Certain combinations are strictly prohibited due to documented interaction-related hazards:

• Hepatitis C Drug Regimens: Co-administration with specific regimens, including those containing ombitasvir/paritaprevir/ritonavir, is formally contraindicated due to the potential for significant liver enzyme elevations (ALT).
• Oral Tranexamic Acid: This combination is prohibited because of a documented pharmacodynamic synergism that increases the risk of thrombotic events.
• Tobacco/Cigarette Smoking: The use of Larissia is contraindicated for females over 35 years old who smoke, due to a heightened, interaction-related risk of serious cardiovascular events.

Pharmacokinetic and Exposure Alterations

The hormones in Larissia are primarily subject to pharmacokinetic interactions that alter their systemic exposure, often via the CYP enzyme system.

• Exposure Decrease: CYP3A4 enzyme inducers (such as Rifampin, Phenytoin, or the herbal product St. John's wort) are documented to decrease the plasma concentrations of the active hormones, which may compromise contraceptive efficacy.
• Exposure Increase: CYP3A inhibitors (such as Itraconazole or Fluconazole) can cause a documented increase in hormone levels. Additionally, certain Statins (e.g., Atorvastatin and Rosuvastatin) are noted to increase the systemic exposure of Ethinyl Estradiol.

Mandatory Administration Constraints

One non-absorbed medicine, Colesevelam, requires a specific time separation to prevent an absorption-related interaction. To avoid the documented reduction in the systemic exposure of Ethinyl Estradiol, Larissia must be administered with a separation of four or more hours from Colesevelam.

Larissia functions through a dual hormonal mechanism involving the progestin levonorgestrel and the estrogen ethinyl estradiol. The components act on the hypothalamic-pituitary-ovarian axis to exert a negative feedback interaction, primarily targeting the pituitary gland.

Levonorgestrel acts as an agonist at the progesterone receptor (PR), while ethinyl estradiol is an agonist at the estrogen receptor (ER). The resulting steroid exposure suppresses the pulsatile release of gonadotropin-releasing hormone (GnRH) from the hypothalamus, leading to a profound reduction in pituitary secretion of the gonadotropins, Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH).

This downstream gonadotropin suppression, particularly the absence of the mid-cycle LH surge, prevents the physiological sequence of follicular rupture and ovum release. Additionally, the progestational activity of levonorgestrel alters the cervical tissue, leading to an increase in cervical mucus viscosity, thereby impeding sperm transit into the superior reproductive tract. The hormonal profile also induces modifications to the endometrium, diminishing its structural receptivity. The collective system-level consequence is the modulation of reproductive processes across three distinct physiological phases.

Larissia is administered orally as a monophasic 28-day regimen tablet for continuous, long-term use. The medication is dosed as one tablet taken once daily at the same time each day, maintaining an interval that does not exceed 24 hours. The fixed dose in each active tablet is Levonorgestrel 0.1 mg and Ethinyl Estradiol 0.02 mg.

The cycle is structured to include 21 consecutive days of active tablets followed by 7 consecutive days of inactive tablets. The entire pack must be taken in the sequential order directed by the blister packaging. Initiation of the first cycle is typically done using either the Day 1 Start (first day of menses) or the Sunday Start method. For the Sunday Start method, non-hormonal back-up contraception is mandated during the first seven days of active tablet intake. The medication is used in postmenarchal females following the same adult regimen.

Dosing Scope	Official Administration Guidelines
Route/Frequency	Oral, once daily, at the same time each day.
Dosing Cycle	21 days active tablets / 7 days inactive tablets.
Age-Group Rule	Used in postmenarchal females following the same adult regimen.

Tablets may be taken with or without food. If an active tablet is missed, there are specific procedural instructions that depend on the number of pills missed and the week of the cycle. These detailed steps must be strictly followed, as deviation from the required 24-hour interval or the sequential order compromises the usage protocol.

Research evidence / Overview of studies for Larissia

Evidence for use in Preventing Pregnancy (Contraception)

Studies concerning the primary purpose of Larissia was studied for its role in researching contraception in women of reproductive age. The core evidence for this use comes primarily from Phase III randomized clinical trials (RCTs) that research examined outcomes related to contraception over a typical period of one year. The outcomes measured in these studies focused on calculating the rate of unintended pregnancies, often expressed as the Pearl Index, which is a key measure relevant in evidence describing how study outcomes are reported.

The trials data show patterns related to contraceptive outcomes when the medication is used exactly as directed. However, the reported outcomes also indicate that the measurements of contraception are dependent upon the consistency and reliability with which the medication was observed in the study populations.

Evidence for use in Menstrual Symptom Management

The combined oral contraceptive (COC) class, which includes Larissia, was evaluated in research exploring the condition frame of conditions characterized by fluctuating or episodic manifestations where symptoms may vary in intensity. The studies explored outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level in women experiencing these symptoms.

Evidence related to Menstrual Pain (Dysmenorrhea)

These studies monitored changes in pain intensity using standardized measures, comparing groups receiving COCs to those receiving a placebo or no treatment. Findings describe patterns observed in the studies where participants reported how symptoms evolved in the observed populations during treatment cycles. However, the evidence quality varies across studies for the COC class, and data specifically for this exact dose combination in comparison to placebo may be heterogeneous.

Evidence related to Excessive Blood Loss (Menorrhagia)

Research examined the effect on blood loss volume and the ability to establish a more predictable menstrual rhythm. The data show patterns related to cycle control, but the body of comparative evidence is limited for some non-contraceptive findings specifically involving this formulation.

Evidence for Androgen-Related Manifestations (Hormonal Acne)

Larissia was studied for conditions where symptoms may vary in intensity, such as hormonal acne, in trials where the formulation was evaluated in women 14 years of age with moderate facial acne. The findings indicate measurements of lesion counts and assessment scores that were observed in both the active treatment group and the placebo group.

Research Gaps and Uncertainties

Research evidence is limited regarding the full spectrum of long-term physiological changes that may be associated with continuous use of the specific low-dose combination found in Larissia. Findings were mixed or inconsistent in some trials exploring secondary outcomes, and certainty remains low for some non-contraceptive findings when compared to the established evidence of the class. The research is ongoing across the field, and current study results reflect the specific conditions under which they were conducted.

Key Studies & References

1. ACOG Practice Bulletin No. 191: Clinical Management of Abnormal Uterine Bleeding

Common questions about Larissia (FAQ)

Q: How long does it usually take for Larissia to start working?

Official directions indicate that when starting the medication using certain methods, such as the Sunday Start, additional contraceptive protection is necessary. The labeling requires use of a non-hormonal contraceptive method for the first seven consecutive days of taking the active tablets to help prevent pregnancy.

Q: Are there any long-term side effects associated with Larissia use?

Official regulatory documents contain a Boxed Warning highlighting an increased risk of serious cardiovascular events with use, such as blood clots, heart attack, and stroke. Other clinically significant risks documented include gallbladder disease and rare liver tumors. These risks are detailed in the Warnings and Precautions section of the prescribing information.

Q: What types of over-the-counter medicines interact with Larissia?

Official product information emphasizes the need for caution with nonprescription (over-the-counter) medicines and herbal products. Specifically, the herbal product St. John's wort is known to interact with the active hormones, which may compromise how the medication works. Consultation with a healthcare provider is generally indicated to review all co-administered products.

Q: Are there any specific foods or supplements that should be avoided with Larissia?

Official product information indicates that grapefruit or grapefruit juice may interact with the medication. This potential interaction could change the systemic exposure of the hormones. For this reason, official information suggests that consumption of grapefruit is avoided.

Q: Does Larissia impact fertility in men or women?

Studies and official information indicate that the hormonal effects of combined contraceptives, like Larissia, are described as reversible. Evidence generally suggests that previous use of the medication does not have a lasting negative impact on a woman's ability to conceive after stopping treatment.

Q: Are there any specific activities or driving restrictions while taking Larissia?

Official warnings specify a restriction related to major medical procedures and extended periods of non-movement. The labeling indicates discontinuation of the medication is required at least four weeks prior to and for two weeks following major surgery or any period of prolonged immobilization.

Q: Is it necessary to have routine blood tests while taking Larissia?

Official prescribing information describes that monitoring is required for specific pre-existing health conditions. For example, monitoring of blood pressure is necessary for those with controlled hypertension, and monitoring of glucose is necessary for prediabetic and diabetic females using the medication.

Q: Does Larissia have a generic version available?

The medication is available in the United States and other markets under its brand name, Larissia. It is also available as several authorized generic versions, all of which contain the exact same active ingredients.

Q: Is it common to feel tired when first starting Larissia?

A feeling of tiredness or weakness is not listed among the most frequent side effects, which typically include headache and nausea. However, official information notes that this symptom is possible and may relate to a serious, clinically significant risk, such as liver problems. The appearance of this symptom is noted as a reason for medical evaluation.

Q: Is it safe to drink alcohol while taking Larissia?

The official prescribing information and drug interaction warnings do not list a specific formal interaction or contraindication with alcohol.

Q: Can Larissia be used by people with kidney problems?

Regulatory documents indicate that the medication is generally used with caution in females with renal (kidney) impairment. Use may be prohibited or require special consideration in patients with severe conditions such as those requiring hemodialysis or peritoneal dialysis.

Q: Can Larissia make me sensitive to the sun?

Official warnings state that the medication may cause or worsen melasma, which presents as blotchy, dark areas on the skin. The official guidance for this risk advises limiting sunlight and artificial UV exposure, as well as using protective measures like sunscreen.

Q: Is Larissia a controlled substance?

The official prescribing information, based on governmental standards, does not classify this medication as a controlled substance.

Q: What is the risk of dependence or addiction with Larissia?

The official prescribing information and safety documentation for this medication does not list a risk of dependence or addiction.

Q: What is the difference between a side effect and an allergic reaction to Larissia?

Official patient warnings define an allergic reaction as a distinct, emergency situation marked by severe symptoms like hives, swelling of the face, tongue, or throat, and difficulty breathing. These reactions are separate from the common, non-emergency side effects such as nausea, headache, or breast tenderness.

Q: Can I crush or split the Larissia tablet if I have trouble swallowing?

The official instruction is that the tablets are taken by mouth in the exact order directed on the package. The tablets are to be swallowed whole, unless there is a specific, alternative direction provided in the medication’s prescribing information for a particular formulation.

Q: Can I buy Larissia online without a prescription?

According to regulatory classifications, Larissia is a prescription-only medication. The drug is dispensed only upon presentation of a valid prescription.

Q: What should I do if I accidentally take too much Larissia?

In cases of accidental ingestion of too much medication, contacting a poison control center or seeking emergency medical help immediately is generally the course of action indicated. Possible symptoms of taking too much include nausea, vomiting, breast tenderness, and heavy vaginal bleeding.

How to Store and Dispose of Larissia?

Larissia (levonorgestrel and ethinyl estradiol tablets) must be stored at a Controlled Room Temperature (CRT), maintaining a temperature between 20 C and 25 C (68 F and 77 F). Brief temperature excursions are acceptable between 15 C and 30 C (59 F and 86 F). To ensure product quality, the medication must be kept in its original container.

Child Safety and Disposal

It is a mandatory regulatory requirement to keep Larissia and all medicines out of the sight and reach of children.

Disposal of any unused or expired tablets must be completed in accordance with local regulations for pharmaceutical waste. Do not dispose of the medication by flushing it down the toilet or placing it in general household trash, unless specifically advised by a regulated medicine take-back program.